CliffBio
biologic

Rotarix

Rotavirus Vaccine, Live, Oral

Loss of exclusivityNovember 2034projected — 12-year biologic exclusivity estimate
CompanyGlaxoSmithKline Biologicals

Drug detail

Brand nameRotarix
Active ingredientRotavirus Vaccine, Live, Oral
Strength106.0CCID50
Dosage formSuspension
RouteOral
ModalityBiologic
FDA approvalNovember 2022
Marketing statusRx

More from GlaxoSmithKline Biologicals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Rotarix patent cliff — loss of exclusivity November 2034 | CliffBio